Canton Strategic Holdings (CNTN) Income from Continuing Operations (2021 - 2026)
Canton Strategic Holdings' (CNTN) quarterly Income from Continuing Operations came in at 47343197.0 in Q1 2026, down 1762.66% YoY from 2847444.25 in Q1 2025, and down 248.26% on a QoQ basis from 13594306.0 in Q4 2025.
Powered by 
Analysis
Canton Strategic Holdings (CNTN) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Canton Strategic Holdings (CNTN) has 6 years of Income from Continuing Operations data on file, last reported at 47343197.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 1762.66% year-over-year to 47343197.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 64894494.0 (down 421.27% YoY) and the FY2025 annual result came in at 42942836.0, down 252.06% from the prior year.
- Income from Continuing Operations declined to 47343197.0 in Q1 2026, from 13594306.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 197435.0 in Q4 2022 to a low of 47343197.0 in Q1 2026.
- A 5-year average of 5636661.59 and a median of 2336914.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 45.09% — and 2026, when it slumped 1762.66%.
- Tracing CNTN's Income from Continuing Operations over 5 years: stood at 197435.0 in 2022, then plunged by 1152.96% to 2473777.0 in 2023, then slumped by 53.08% to 3786758.0 in 2024, then sank by 259.0% to 13594306.0 in 2025, then plunged by 248.26% to 47343197.0 in 2026.
- The last three Income from Continuing Operations figures came in at 47343197.0 (Q1 2026), 13594306.0 (Q4 2025), and 2101838.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Canton Strategic Holdings | 493.37 Mn | 493.37 Mn | - | -17.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.95 Mn |
| Mar 31, 2026 | -47.34 Mn |
| Dec 31, 2025 | -13.59 Mn |
| Sep 30, 2025 | -2.10 Mn |
| Jun 30, 2025 | -1.43 Mn |
| Mar 31, 2025 | -2.54 Mn |
| Dec 31, 2024 | -3.82 Mn |
| Sep 30, 2024 | -3.80 Mn |
| Jun 30, 2024 | -2.33 Mn |
| Mar 31, 2024 | -2.26 Mn |
| Dec 31, 2023 | -2.47 Mn |
| Sep 30, 2023 | -1.82 Mn |
| Jun 30, 2023 | -2.34 Mn |
| Mar 31, 2023 | -2.69 Mn |
| Dec 31, 2022 | -1.76 Mn |
| Sep 30, 2022 | -2.13 Mn |
| Jun 30, 2022 | -1.64 Mn |
| Mar 31, 2022 | -2.95 Mn |
| Dec 31, 2021 | -359,870.00 |
| Sep 30, 2021 | -777,113.00 |